Search Results
Jul 24, 2026, 08:00 ET Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Jul 23, 2026, 21:30 ET Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
unblinded and continue without modification. At that time, Laminar Pharma reported a potential clinically relevant improvement in progression-free survival (PFS) for MGMT-methylated patients receiving LAM561 plus SoC compared to the placebo control group. Laminar Pharma's commitment to international ethical principles
More news about: Laminar Pharmaceuticals, S.A.
Jul 23, 2026, 21:30 ET Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
unblinded and continue without modification. At that time, Laminar Pharma reported a potential clinically relevant improvement in progression-free survival (PFS) for MGMT-methylated patients receiving LAM561 plus SoC compared to the placebo control group. Laminar Pharma's commitment to international ethical principles
More news about: Laminar Pharmaceuticals, S.A.
Jul 23, 2026, 10:31 ET ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight
efficacy.Later-generation ALK inhibitors, including Alectinib and Lorlatinib, have shown substantial improvements in progression-free survival (PFS) and intracranial disease control compared with first-generation therapies, establishing new standards of care for patients with ALK-positive NSCLC.The
More news about: DelveInsight Business Research, LLP
Jul 23, 2026, 10:10 ET AbelZeta announces publication in Nature journal highlighting clinical findings for an armored autologous GPC3 CAR-T therapy in patients with advanced hepatocellular carcinoma
(ORR) was 44.4%, and the median duration of response (DOR) was 4.4 months (95% confidence interval: 2.9–7.4).Median progression-free survival (PFS) was 4.2 months (95% confidence interval: 2.9–4.8).Median overall survival (OS) was 14.2 months (95% confidence interval: 10.1 to not evaluable).Safety
More news about: AbelZeta Pharma, Inc.
Jul 23, 2026, 10:09 ET SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
therapies.A protocol amendment expanded the PFS analysis population to include all patients with at least 6 months of follow-up.The study ultimately did not reach statistical significance for its primary endpoint of improved PFS.Alleged SEC Disclosure Adequacy
More news about: SueWallSt.com
Jul 23, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.Pomerantz LLP, with
More news about: Pomerantz LLP
Jul 23, 2026, 09:00 ET INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Jul 23, 2026, 08:30 ET TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
line of therapy, including an anti-CD38 antibody and lenalidomide.1 Both the Tec-Tal and Tal-P regimens met the study's primary endpoint of PFS, demonstrating statistically significant and clinically meaningful improvements versus standard of care.1 Risk of progression or death was
More news about: Johnson & Johnson
Jul 23, 2026, 06:50 ET MAYFAIR GOLD PROVIDES Q2 2026 UPDATE ON FENN-GIB PROJECT ADVANCEMENT AND DE-RISKING ACTIVITIES
Study (the "PFS") is to develop the Project under the provincial permitting process, targeting the higher-grade 1 million ounce probable mineral reserve (25.1Mt at an average grade of 1.29 g/t) sitting near-surface, highlighting the optionality and scalability provided by the deposit. The PFS also outlines
More news about: Mayfair Gold Corp.
Jul 22, 2026, 16:33 ET AAOS sounds alarm on CMS Medicare proposal that drives consolidation and harms patient access to care
Surgeons (AAOS) today expressed alarm with the Centers for Medicare & Medicaid Services' (CMS) calendar year 2027 Medicare Physician Fee Schedule (PFS) proposed rule and urges CMS to withdraw the proposed policies that threaten patient access to high-quality musculoskeletal care.
More news about: American Association of Orthopaedic Surgeons
Jul 22, 2026, 09:00 ET INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Jul 22, 2026, 08:45 ET New Zealand's Gold and Antimony Renaissance Is Attracting Serious Capital. This Dual-Project Explorer Just Made Its Board Match Its Ambitions.
production profile in the PEA could prove optimistic. The technical studies feeding the PFS, metallurgical testing, geotechnical characterization, and hydrogeological work — carry their own uncertainties. A completed PFS that differs materially from the PEA's parameters would require the market to reassess
More news about: USA News Group
Jul 21, 2026, 19:00 ET Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges
More news about: Hagens Berman Sobol Shapiro LLP
Jul 21, 2026, 10:07 ET The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." Following this news, the price of Regeneron's common stock declined even further. From a closing market price of $698.25 per share on May 15, 2026,
More news about: The Gross Law Firm
Jul 20, 2026, 08:00 ET Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
Response Assessment in Neuro-Oncology (RANO) for low grade gliomas (LGG) criteria, was 51.9%. Median progression-free survival (PFS) was not reached, and the 36-month PFS rate was 79.1%. Responses were durable, with only one patient who had previously responded experiencing subsequent disease
More news about: Nuvation Bio Inc.
Jul 17, 2026, 10:00 ET REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc.
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, the price of Regeneron's common stock declined from $698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026, a decline
More news about: Robbins LLP
Jul 17, 2026, 08:30 ET America Wants a Uranium Supply Chain and an AI-Ready Reactor Fleet, and One Nasdaq Company Is Trying to Build Both at Once
agreements with BBA USA Inc. and SLR International Corporation, which together complete the roster of major operational contractors for the planned PFS-related drill program at Aurora. Each carries a defined mandate: Yukuskokon provides turnkey project management and geological support; BBA handles real-time
More news about: Equity Insider
Jul 17, 2026, 08:00 ET SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
supported by results from the pivotal PANKU-Esophagus01 (BL-B01D1-305) study. The study met both dual primary endpoints of progression-free survival (PFS) and overall survival (OS), demonstrating statistically significant and clinically meaningful improvements versus chemotherapy, while maintaining a manageable
More news about: SystImmune, Inc.
Jul 15, 2026, 09:50 ET Tanzania's Next Gold Mine Has Its Team, Its Financing, and Its Permits - Now It Just Has to Build
therefore is not independent of the Company. Cautionary Note on Production Decision: Although Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: USA News Group
Jul 14, 2026, 19:30 ET Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS and a positive OS trend compared with pembrolizumab plus pemetrexed and platinum-based chemotherapy.Focusing on the particularly challenging
More news about: Kelun-Biotech
Jul 13, 2026, 07:00 ET Defense Metals Provides Corporate Update Highlighting Continued Execution and Strategic Momentum
reserve, as detailed in the Company's 2025 Pre Feasibility Study ("PFS"; refer to Company News Release April 7th, 2025) prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects. The PFS shows the economic potential of the deposit and supports future
More news about: Defense Metals Corp.
Jul 09, 2026, 05:28 ET InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
prevent or significantly delay treatment resistance.Prolonged survival benefit of PFS and overall survival (OS): The mPFS reached an extraordinary 22.3 months (95% CI: 9.6–NE), with 12-month and 18-month PFS rates standing at 67.9% and 58.2%, respectively. The median OS was 27.8 months (95% CI:
More news about: InxMed Co., Ltd
Jul 08, 2026, 09:06 ET Gold Above $4,100: The Race To Build Africa's Next Gold Mines Is On
therefore is not independent of the Company. Cautionary Note on Production Decision: Although Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: Equity Insider
Jul 08, 2026, 09:00 ET As Washington Races to Rebuild Domestic Uranium Supply, One Nasdaq Company Is Lining Up the Team at American's Largest Conventional, Measured and Indicated Uranium Deposit
planned Pre-Feasibility Study (PFS)-related work program at the Aurora Uranium Project.The Company said it is now awaiting permit approvals from state-level regulators in Oregon before commencing drilling at Aurora, which sits along the Oregon-Nevada border, with the PFS expected to be completed
More news about: USA News Group